1-5 of 5
Sylvie Guichard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Stephane De Botton, Karen Yee, Christian Recher, Andrew H. Wei, Pau Montesinos, David Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Jordi Esteve, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Olivier Legrand, Pierre Peterlin, Montserrat Arnan Sangerman, William G. Blum, Daniela Cilloni, Devendra Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin Watts, Jay Yang, Zihao Xin, Alex Sedkov, Sylvie Guichard, Jennifer Sweeney, Christophe Marzac, Jorge E. Cortes, Pierre Fenaux
Journal: Blood
Blood (2021) 138 (Supplement 1): 2351.
https://doi.org/10.1182/blood-2021-144912
Published: 2021
Journal Articles

Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels

Archana Shrestha, Mengna Chi, PhD, Kimberly Wagner, Adam Drake, Keertik Fulzele, PhD, Sylvie Guichard, Punam Malik, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-140875
Published: 2020
Journal Articles

Ex-Vivo FT-4202 Treatment Improves Hemoglobin Oxygen Affinity and Membrane Health in Red Blood Cells of Patients with Hemoglobin SS and Hemoglobin SC Disease Irrespective of Prior Hydroxyurea Use

Diamantis G. Konstantinidis, PhD BSc, Rose Fessler, Katie Giger Seu, PhD, Bhargav Patel, Jennifer B Korpik, Keertik Fulzele, PhD, Sylvie Guichard, Theodosia A. Kalfa, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-139714
Published: 2020
Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 674.
https://doi.org/10.1182/blood-2019-124360
Published: 2019
Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Justin M. Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Thomas Prebet, MD PhD, Sangmin Lee, MD, Gary J. Schiller, MD, Shira Dinner, MD, Arnaud Pigneux, Pau Montesinos, MD PhD, Eunice S. Wang, MD, Karen Seiter, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Stephane De Botton, Montserrat Arnan Sangerman, William B. Donnellan, MD, Brian A Jonas, MD PhD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Patrick Kelly, MD, Jennifer Sweeney, Sanjeev Forsyth, Sylvie Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 231.
https://doi.org/10.1182/blood-2019-123920
Published: 2019